About Suzhou Zelgen Biopharmaceuticals Company

The company was founded in 2009 and is located in Kunshan National High-tech Zone, Jiangsu Province. It has 5 subsidiaries: Gensun Biopharmaceutical Company of the United States, Shanghai Zejing Pharmaceutical Technology Co., Ltd., Suzhou Zejing Biotechnology Co., Ltd., Zejing Pharmaceutical (Zhejiang) Co., Ltd., and Zejing Holdings Co., Ltd. Zejing Pharmaceutical is committed to independent R&D, production and commercialization of innovative drugs. The company is an innovative pharmaceutical company focusing on various treatment fields such as tumors, hemorrhagic and hematologic diseases, immune inflammatory diseases, and hepatobiliary diseases. Main products: Donafinil toluene sulfonate tablets, dicaxitinib hydrochloride tablets, recombinant human thrombin, injectable recombinant human thyroid-stimulating hormone, 8 new drugs under clinical phase I/II development, etc. The company has successively completed 5 national “major new drug creations”, 1 national science and technology innovation fund for small and medium-sized enterprises, and a number of Jiangsu provincial science and technology projects; the company has applied for 286 invention patents, of which 115 have been granted invention patents in China, the United States, the European Union and other countries and regions.